On September 18, 2023, HC Wainwright released its earnings per share (EPS) estimates for Roivant Sciences Ltd. (NASDAQ: ROIV) for the first quarter of 2027. Analyst D. Tsao anticipates that Roivant will report earnings of ($0.26) per share for the upcoming quarter. The firm maintains a “Buy” rating on the stock and has set a price target of $20.00.
The consensus estimate for Roivant’s full-year earnings currently stands at ($0.92) per share. HC Wainwright also provided estimates for subsequent quarters, predicting losses of ($0.32) in Q2, ($0.33) in Q3, and ($0.34) in Q4 of 2027. Overall, the firm projects full-year losses of ($1.25) per share.
Multiple analysts have recently reassessed their ratings for Roivant. Leerink Partners raised its target price from $18.00 to $22.00, assigning an “outperform” rating. Similarly, Guggenheim increased its price target from $15.00 to $21.00 and maintained a “buy” rating. Citigroup initiated coverage with a “buy” rating and a target of $16.00. Meanwhile, Goldman Sachs lifted its target from $20.00 to $24.00, also giving the stock a “buy” rating. Bank of America adjusted its target from $12.00 to $16.50 and assigned a “neutral” rating.
According to MarketBeat.com, Roivant Sciences currently has a consensus rating of “Buy” and an average price target of $19.94.
Stock Performance and Market Position
As of Monday, Roivant Sciences opened at $14.74. The company boasts a market capitalization of $10.07 billion and shows a price-to-earnings ratio of -21.06. Its 50-day moving average is $12.35, while the 200-day moving average is $11.34. The stock has fluctuated significantly over the past year, with a low of $8.73 and a high of $16.05.
Institutional investors are actively engaging with Roivant’s stock. Notable activities in the first quarter included Parallel Advisors LLC increasing its stake by 80.5%, and CWM LLC expanding its holdings by 44.6% during the second quarter. Additionally, UMB Bank n.a. grew its stake by 112.7%, while Fifth Third Bancorp raised its stake by 59.3%. Collectively, institutional investors own 64.76% of the company’s stock.
Insider Transactions and Ownership Changes
In recent insider trading activities, Eric Venker, the CEO of Roivant, sold 683,818 shares of the company on September 19, 2023, at an average price of $14.95, totaling approximately $10,223,079.10. Following this transaction, Venker holds 1,969,767 shares, valued at about $29,448,016.65, representing a 25.77% decrease in his ownership.
Another notable transaction involved major shareholder Vivek Ramaswamy, who sold 1,195,000 shares at an average price of $12.50 on September 3, 2023, amounting to $14,937,500.00. Post-transaction, Ramaswamy still owns 36,089,108 shares, valued at around $451,113,850, signifying a 3.21% reduction in ownership.
Over the past three months, insiders have collectively sold 3,686,749 shares of Roivant stock, valued at approximately $50,302,987. Currently, company insiders hold 10.80% of Roivant Sciences.
Roivant Sciences Ltd. is a commercial-stage biopharmaceutical firm focused on developing and commercializing medicines in the areas of inflammation and immunology. The company employs a model known as “Vants” to advance its biopharmaceutical businesses, discovery-stage companies, and health technology startups.
For further updates on Roivant Sciences and related companies, interested parties can subscribe to MarketBeat.com’s daily email newsletter, which provides concise summaries of the latest news and analysts’ ratings.
